Which agent is described as an emerging nerve growth factor-3 inhibitor for osteoarthritis?

• A. Levicept
• B. MTX
• C. Prednisone
• D. NSAIDs

Answer: (B)

Emerging nerve growth factor inhibitors work by directly blocking NGF signaling to reduce pain transmission in osteoarthritis. NGF normally binds to receptors on pain-sensing nerves, lowering their sensitivity and amplifying pain. By neutralizing NGF with monoclonal antibodies, these therapies can lessen OA pain more specifically than standard analgesics. Examples in development include anti-NGF antibodies like tanezumab, fasinumab, and fulranumab, which are designed to dampen pain signaling rather than simply masking symptoms.

Among the options listed, none are anti-NGF agents. Methotrexate is a disease-modifying drug used mainly for inflammatory arthritis, not an NGF inhibitor. NSAIDs reduce pain and inflammation by inhibiting COX enzymes but do not target NGF. Prednisone is a corticosteroid with broad anti-inflammatory effects, not NGF-directed. Levicept targets VEGF rather than NGF. Therefore, the described emergent NGF-inhibitor therapy would be an anti-NGF antibody such as tanezumab, not any of these agents.